Patent · US Active

Mutation signatures for predicting the survivability of myelodysplastic syndrome subjects

US10711308B2 · kind B2 · utility

0Cited by
0References
31Claims
0Family size

Assignees

Inventors

Key dates

Filing dateJun 15, 2012
Grant dateJul 14, 2020
Priority date—
Expiry dateNov 22, 2033

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC12Q2600/156
  • WIPO fieldBiotechnology
  • WIPO sectorChemistry

Abstract

Somatic non-silent mutations on selected biomarkers are reliable indicators for the overall survival of Myelodysplastic Syndrome subjects.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.